Effects of stress and behavioral interventions in hypertension: the rise and fall of omapatrilat.
作者信息
Pickering Thomas G
机构信息
Integrative and Behavioral Cardiovascular Health Program, Zena and Michael Wiener Cardiovascular Institute, Mt. Sinai School of Medicine, New York, NY 10029, USA.
出版信息
J Clin Hypertens (Greenwich). 2002 Sep-Oct;4(5):371-3. doi: 10.1111/j.1524-6175.2002.01506.x.
Abstract
摘要
相似文献
1
Effects of stress and behavioral interventions in hypertension: the rise and fall of omapatrilat.
J Clin Hypertens (Greenwich). 2002 Sep-Oct;4(5):371-3. doi: 10.1111/j.1524-6175.2002.01506.x.
2
Omapatrilat.
Circulation. 2002 Aug 6;106(6):e9011-2.
3
[A new class of potent antihypertensive agents. Especially systolic pressure is significantly reduced].
MMW Fortschr Med. 1999 Nov 25;141(47):8.
4
Vasopeptidase inhibition and angio-oedema.
Lancet. 2000 Aug 19;356(9230):608-9. doi: 10.1016/S0140-6736(00)02596-4.
5
[Vasopeptidase inhibition: a new mechanism of action--a new antihypertensive drug].
Praxis (Bern 1994). 2000 Apr 13;89(16):649-53.
6
Is omapatrilat a novel therapy of the past rather than the future?
Drugs. 2004;64(6):630-1; author reply 631. doi: 10.2165/00003495-200464060-00007.
7
Omapatrilat may indeed not be much superior (OMINOUS).
Int J Cardiol. 2003 Sep;91(1):113. doi: 10.1016/s0167-5273(02)00593-4.
8
Effects of omapatrilat in low, normal, and high renin experimental hypertension.
Am J Hypertens. 1998 Mar;11(3 Pt 1):363-72. doi: 10.1016/s0895-7061(97)00404-4.
9
Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.
Am J Hypertens. 2004 Feb;17(2):103-11. doi: 10.1016/j.amjhyper.2003.09.014.
10
Omapatrilat--the story of Overture and Octave.
Int J Cardiol. 2002 Nov;86(1):1-4. doi: 10.1016/s0167-5273(02)00389-3.
引用本文的文献
1
2
Combination therapy is it in the future for successfully treating peripheral diabetic neuropathy?
Front Endocrinol (Lausanne). 2024 May 15;15:1357859. doi: 10.3389/fendo.2024.1357859. eCollection 2024.
3
Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control.
Ther Adv Endocrinol Metab. 2020 Dec 25;11:2042018820970444. doi: 10.1177/2042018820970444. eCollection 2020.
4
Targeting Metalloenzymes for Therapeutic Intervention.
Chem Rev. 2019 Jan 23;119(2):1323-1455. doi: 10.1021/acs.chemrev.8b00201. Epub 2018 Sep 7.
5
Comprehensive review of cardiovascular toxicity of drugs and related agents.
Med Res Rev. 2018 Jul;38(4):1332-1403. doi: 10.1002/med.21476. Epub 2018 Jan 5.
6
Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.
Pharmacol Res. 2017 Nov;125(Pt A):57-71. doi: 10.1016/j.phrs.2017.05.020. Epub 2017 May 29.
7
Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond.
Vasc Health Risk Manag. 2015 Jun 1;11:283-95. doi: 10.2147/VHRM.S55630. eCollection 2015.
8
Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
J Clin Hypertens (Greenwich). 2006 Sep;8(9):649-56; quiz 657-8. doi: 10.1111/j.1524-6175.2006.05689.x.
9
Recent clinical trials with omapatrilat: new developments.
Curr Hypertens Rep. 2003 Aug;5(4):346-52. doi: 10.1007/s11906-003-0045-6.
本文引用的文献
1
Results from late-breaking clinical trial sessions at the American College of Cardiology 51st Annual Scientific Session.
J Am Coll Cardiol. 2002 Jul 3;40(1):1-18. doi: 10.1016/s0735-1097(02)01982-4.
2
Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure.
Am Heart J. 2002 Jun;143(6):1112-7. doi: 10.1067/mhj.2002.123111.
3
Vasopeptidase inhibitors: a bradykinin link.
Lancet. 2002 Mar 30;359(9312):1157-8. doi: 10.1016/S0140-6736(02)08142-4.
4
Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial.
Am J Hypertens. 2002 Feb;15(2 Pt 1):193-8. doi: 10.1016/s0895-7061(01)02048-9.
5
Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients.
Hypertension. 2001 Dec 1;38(6):1342-8. doi: 10.1161/hy1201.096569.
6
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience.
Control Clin Trials. 2001 Dec;22(6):659-73. doi: 10.1016/s0197-2456(01)00176-3.
7
Efficacy and safety of omapatrilat with hydrochlorothiazide for the treatment of hypertension in subjects nonresponsive to hydrochlorothiazide alone.
Am J Hypertens. 2001 Aug;14(8 Pt 1):788-93. doi: 10.1016/s0895-7061(01)01294-8.
8
Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial.
Hypertension. 2001 Jan;37(1):12-18. doi: 10.1161/01.hyp.37.1.12.
9
Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991.
Hypertension. 1995 Jul;26(1):60-9. doi: 10.1161/01.hyp.26.1.60.
10
Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension.
J Hypertens. 1992 Jul;10(7):607-13.
Zotero 插件